Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095558 | 0.83 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL14162629 | 0.83 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL28905989 | 0.83 | TDP1 (0.44) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL17080164 | 0.80 | PARP15 (0.47) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL6302841 | 0.77 | SLC6A3 (0.38) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL20809605 | 0.72 | SMN1; SMN2 (0.48) | RAB9ANPC1SMN1; SMN2TDP1CYP3A4 | |
| SCHEMBL20809614 | 0.71 | NAMPT (0.37) | CYP3A4ACACB | |
| SCHEMBL3505544 | 0.71 | ALDH1A1 (0.36) | LMNA | |
| SCHEMBL27758216 | 0.71 | DGKA (0.45) | RAB9ANPC1SMN1; SMN2TDP1PARP15 | |
| SCHEMBL2095004 | 0.70 | TRPM8 (0.36) | RAB9ANPC1SMN1; SMN2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | GAP43, NCDN, NLN | RAB9A 2653/4885NPC1 288/4885SMN1; SMN2 203/4885 |
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | GAP43, NCDN, NLN | RAB9A 2653/4885NPC1 288/4885SMN1; SMN2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.